Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 58, 2190-2195, May 15, 1998]
© 1998 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aurelio, O. N.
Right arrow Articles by Stanbridge, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aurelio, O. N.
Right arrow Articles by Stanbridge, E. J.

Germ-Line-derived Hinge Domain p53 Mutants Have Lost Apoptotic but not Cell Cycle Arrest Functions1

Oscar N. Aurelio2, Jean-Francois Cajot2,3,, Mai L-H. Hua, Zeenat Khwaja and Eric J. Stanbridge4

Department of Microbiology and Molecular Genetics, University of California-Irvine, Irvine, California 92697-4025

The protein p53 is a critical tumor suppressor, as demonstrated by its frequent mutation in human cancers. Overexpression of the wild-type form of the p53 tumor suppressor gene in human cancer cell lines has been shown to lead to either cell cycle arrest or apoptosis. A study of two Li-Fraumeni syndrome-derived p53 hinge domain mutants shows that both mutants retain the ability to arrest cell growth but are significantly impaired for the induction of apoptosis in human p53-null cell lines. This indicates that the hinge domain may be important in the regulation of p53-dependent apoptosis.

1 Supported by National Cancer Institute Grants CA19401 and CA68230. O. N. A. is supported in part by National Cancer Institute/National Institute of General Medical Sciences Fellowship 1F31CA7718-01.

2 O. N. A. and J-F. C. contributed equally to this study.

3 Present address: Department of Experimental Pathology, Swiss Institute of Experimental Cancer Research (ISREC) 1066 Epalinges, Switzerland.

4 To whom requests for reprints should be addressed, at Dept. of Microbiology and Genetics, University of California-Irvine, Irvine, CA 92697-4025.

Received 10/29/97. Accepted 3/19/98.




This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
B. W. Kirk, M. Feinsod, R. Favis, R. M. Kliman, and F. Barany
Single nucleotide polymorphism seeking long term association with complex disease
Nucleic Acids Res., August 1, 2002; 30(15): 3295 - 3311.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
O. N. Aurelio, X.-T. Kong, S. Gupta, and E. J. Stanbridge
p53 Mutants Have Selective Dominant-Negative Effects on Apoptosis but Not Growth Arrest in Human Cancer Cell Lines
Mol. Cell. Biol., February 1, 2000; 20(3): 770 - 778.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
X.-T. Kong, H. Gao, and E. J. Stanbridge
Mechanisms of Differential Activation of Target Gene Promoters by p53 Hinge Domain Mutants with Impaired Apoptotic Function
J. Biol. Chem., August 24, 2001; 276(35): 32990 - 33000.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1998 by the American Association for Cancer Research.